Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
- Associated Therapies
- -
A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT06586606
- Locations
- 🇺🇸
QPS-MRA, LLC ( Site 0001), South Miami, Florida, United States
A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 30
- Registration Number
- NCT06543043
- Locations
- 🇺🇸
Quotient Sciences, Miami, Florida, United States
A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.
- Conditions
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT06541678
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Bruxelles, Bruxelles-Capitale, Belgium
Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT06495944
- Locations
- 🇺🇸
Site 01, Baltimore, Maryland, United States
A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 17
- Registration Number
- NCT06494644
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06492525
- Locations
- 🇨🇳
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 8
- Registration Number
- NCT06421714
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).
- Conditions
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT06406400
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 42
- Registration Number
- NCT06392659
- Locations
- 🇬🇧
MAC Clinical Research, Manchester, United Kingdom
A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- PMV Pharmaceuticals, Inc
- Target Recruit Count
- 12
- Registration Number
- NCT06362642
- Locations
- 🇺🇸
Fortrea, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.